In Nairobi, AIDS activists are celebrating a rare victory. After months of vacillation, the Kenyan parliament recently approved a law allowing for the importation of generic, or copycat, versions of patented anti-retroviral medicines without their patent-holders’ consent. Many people believe that opening the market to generic copies will bring down prices for millions of HIV-infected Kenyans faster than any discount offered by giant drug companies.
Meanwhile, in the Puna highlands of Peru, poor farmers are furious about patents issued to two US companies giving them exclusive rights to market maca, a potato-like plant and popular aphrodisiac, in America. The Peruvians…
Register today to continue reading
You’ve hit your limit of three articles in the last 30 days. To get seven more, simply enter your email address below.
You’ll also receive our free e-book Prospect’s Top Thinkers 2020 and our newsletter with the best new writing on politics, economics, literature and the arts.
Prospect may process your personal information for our legitimate business purposes, to provide you with newsletters, subscription offers and other relevant information.
Click here to learn more about these purposes and how we use your data. You will be able to opt-out of further contact on the next page and in all our communications.
Already a subscriber? Log in here